Research Analysts Issue Forecasts for Surrozen Q1 Earnings

Surrozen, Inc. (NASDAQ:SRZN) – Stock analysts at HC Wainwright boosted their Q1 2026 earnings estimates for Surrozen in a research note issued to investors on Tuesday, March 24th. HC Wainwright analyst M. Caufield now expects that the company will earn ($0.72) per share for the quarter, up from their prior estimate of ($1.20). HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Surrozen’s current full-year earnings is ($8.49) per share. HC Wainwright also issued estimates for Surrozen’s Q2 2026 earnings at ($1.03) EPS, Q3 2026 earnings at ($0.98) EPS, Q4 2026 earnings at ($0.94) EPS, FY2026 earnings at ($3.70) EPS, FY2027 earnings at ($3.70) EPS, FY2028 earnings at ($3.89) EPS and FY2029 earnings at ($3.97) EPS.

Several other research analysts have also recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $40.00 price target on shares of Surrozen in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. Finally, Wall Street Zen upgraded Surrozen to a “sell” rating in a research report on Friday, November 28th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Surrozen has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.

Surrozen Price Performance

NASDAQ SRZN opened at $28.00 on Thursday. The company’s 50 day simple moving average is $24.50 and its two-hundred day simple moving average is $18.87. Surrozen has a 1 year low of $5.90 and a 1 year high of $29.59. The stock has a market capitalization of $239.96 million, a PE ratio of -0.84 and a beta of 0.53.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($7.59) EPS for the quarter, missing the consensus estimate of ($1.29) by ($6.30). The firm had revenue of $0.53 million for the quarter, compared to analysts’ expectations of $0.66 million. Surrozen had a negative net margin of 7,476.67% and a negative return on equity of 1,240.42%.

Insider Activity at Surrozen

In related news, major shareholder Tcg Crossover Gp Ii, Llc purchased 106,658 shares of the business’s stock in a transaction on Tuesday, March 24th. The stock was acquired at an average price of $24.69 per share, with a total value of $2,633,386.02. Following the purchase, the insider directly owned 736,554 shares in the company, valued at approximately $18,185,518.26. This represents a 16.93% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Group Gp Lp Column III purchased 18,052 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was bought at an average cost of $19.60 per share, for a total transaction of $353,819.20. Following the acquisition, the insider directly owned 1,016,658 shares in the company, valued at approximately $19,926,496.80. The trade was a 1.81% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have acquired 330,291 shares of company stock valued at $7,478,785. 45.18% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. increased its stake in Surrozen by 50.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock valued at $34,000 after acquiring an additional 500 shares during the last quarter. Persistent Asset Partners Ltd bought a new stake in Surrozen during the fourth quarter worth about $99,000. Citadel Advisors LLC lifted its stake in Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after purchasing an additional 3,424 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Surrozen in the 4th quarter worth about $247,000. Finally, Geode Capital Management LLC increased its position in shares of Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after purchasing an additional 5,702 shares during the last quarter. 66.57% of the stock is currently owned by hedge funds and other institutional investors.

Surrozen News Summary

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Large insider buys by major shareholder TCG Crossover GP II — the fund bought 106,658 shares on March 24 (~$24.69 avg) and has repeatedly purchased stock in March, signaling strong insider conviction that can support the share price. SEC Filing
• Positive Sentiment: Additional TCG purchase: 15,223 shares on March 23 (~$24.90 avg), a follow-on buy that reinforces the insider buying narrative. InsiderTrades article
• Positive Sentiment: HC Wainwright reiterated a “Buy”, raised multi-quarter and multi-year EPS projections (less negative) and set a $36 price target — a constructive analyst view that can attract demand. Article
• Positive Sentiment: Cantor Fitzgerald assigned an “Overweight” rating with a higher price target (reported this week), providing another institutional buy-side signal. Article
• Neutral Sentiment: Institutional ownership is high (many hedge funds hold SRZN) and several institutions increased positions in recent quarters — supportive for liquidity but not an immediate catalyst.
• Negative Sentiment: Lifesci Capital cut multiple near-term EPS estimates (Q1–Q4 2026 and FY2026), making its outlook more pessimistic and creating downside pressure for sentiment. MarketBeat coverage
• Negative Sentiment: Recent quarterly results (reported March 23) were a significant miss (EPS deeply negative vs. expectations) and the company remains loss-making with volatile margins — a fundamental risk that keeps shares speculative despite positive headlines. Earnings detail

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.